Tag Archives: Xalkori

May, 2018

November, 2016

March, 2016

December, 2015

  • 9 December

    FDA Grants Priority Review for Pfizer’s Xalkori in NSCLC

    Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In April 2015, XALKORI received Breakthrough …

April, 2015